clinical trial · NCT04167761
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Cardiovascular DiseasesAtherosclerosisType 2 DiabetesInsulin ResistanceErtugliflozin
brief summary
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
started
Jul 1, 2020
primary completion
Dec 31, 2023
completion
Dec 31, 2023
last updated
Dec 20, 2024
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol